Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tool could spot hidden diabetes risk in psoriasis patients

NCT ID NCT07321288

Knowledge-focused Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at medical records from over 1,200 psoriasis patients to find who is most likely to develop insulin resistance, a condition that can lead to diabetes. Researchers will use machine learning to build a simple tool that helps doctors estimate this risk. No new treatments are involved—the goal is better early detection and prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a simple tool to identify psoriasis patients at high risk for insulin resistance, enabling earlier monitoring and prevention of diabetes.
What could go wrong
This is an observational study using existing records, so it cannot prove cause and effect. The prediction model may not work well for patients outside the study centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,265 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult patients with psoriasis who received routine clinical care at Chinese PLA General Hospital (First Medical Center) and a collaborating center (Fourth Medical Center) in China. Participants are identified from hospital-based clinical databases and electronic medical records collected during routine dermatology practice between January 2015 and June 2025. The population represents a real-world cohort of patients with psoriasis receiving standard medical care in tertiary hospitals. Data used in this observational study are collected retrospectively, and all patient information is anonymized prior to analysis. No interventions or additional procedures are performed as part of the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Diagnosed with psoriasis (including plaque psoriasis, pustular psoriasis, erythrodermic psoriasis, or other clinically recognized subtypes), according to established clinical diagnostic guidelines * Received medical care at Chinese PLA General Hospital (First Medical Center) or the collaborating center (Fourth Medical Center) during the study period * Availability of complete medical records, including demographic information, relevant clinical characteristics, and laboratory data required to assess insulin resistance Exclusion Criteria: * Previous or current diagnosis of diabetes mellitus * Presence of severe systemic diseases that may significantly affect glucose metabolism (such as malignant tumors, hyperthyroidism, or other serious endocrine disorders) * Current or recent use of systemic medications known to affect insulin sensitivity, including:Systemic corticosteroids,Glucose-lowering medications, or Other medications with known significant effects on insulin resistance * Pregnant or breastfeeding women * Medical records with missing key variables required for the assessment of insulin resistance or model development

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insulin resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Insulin resistance Psoriasis

Contacts and locations

Locations

  • Chinese PLA General Hosptial

    Beijing, None Selected, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.